抗人肝癌铁蛋白抗体对原发性肝癌患者的放射免疫显像

用~(131)Ⅰ标记抗人肝癌铁蛋白抗体对16例原发性肝癌患者作放射免疫显像分析。结果:显像阳性率为81.3％,其中经肝动脉插管和经外周静脉注射者各8例,前者阳性率为100％,注射后当天用单光子发射计算机处理断层摄影即可获得阳性显像,以第4～6天显像最为清晰,有3例追踪到第20天仍可获阳性显像。后者阳性率为62.5％,以第5～7天显像最为清晰。第3、5和8天肝癌与周围肝组织的中位放射强度比值前者分别为1.4,1.6和1.8,最高可达2.9;后者分别为1.2、1.3和1.4最高达1.8。

RADIOIMMUNOIMAGING OF PRIMARY LIVER CANCER IN PATIENTS WITH 131I LABELED ANTI-HUMAN EEP-ATOCELLULAR CARCINOMA ISOFERRITIN ANTIBODY

Radioimmnnoimaging of primary liver cancer in 16 patients using 131-I labeled anti-human hepatocellular carcinoma isoferritin antibody (131-I FtAb) was reported. The positive imaging rate was 81.3% in the entire series. In 8 patients with administration of 131-I FtAb via hepatic artery catheters, tumors wore visualized in all of the patients (100%). Positive imaging was shown on the same day and became clearest on day 4-6 after administration. The median radioactivity ratio of tumor to normal liver on day 3, 5 and 8 were 1.4, 1.6 and 1.8 respectively and the highest was 2.9. In another 8 patients with the administration of 131-1 FtAb via peripheral vein, the positive imaging rate was 62.5 % (5/8) and the median radioactivity ratio was lower than that via hepatic artery administration, being 1.2, 1.3 and 1.4 respectively with the highest of 1.8.